tetano
Editor, Senior Moderator
Am J Transplant. 2011 Sep 11. doi: 10.1111/j.1600-6143.2011.03743.x. [Epub ahead of print]
Impact of Adjuvanted H1N1 Vaccine on Cell-Mediated Rejection in Heart Transplant Recipients.
Schaffer AS, Husain S, Delgado DH, Kavanaugh L, Ross RJ.
Source
Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada Division of Transplantation, Toronto General Hospital, University Health Network, Toronto, ON, Canada Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada.
Abstract
During the H1N1 influenza virus pandemic, vaccination of high risk groups including solid-organ transplant recipients was advised. A retrospective case control study of 60 heart transplant patients, 15 having received the H1N1 virus antigen and ASO3 adjuvant vaccine (GlaxoSmithKline, Mississauga, ON, Canada) within 21 days and 45 having not been vaccinated, all undergoing routine surveillance endmyocardial biopsies, was performed. The overall rate of cellular rejection (all grades) was not statistically different between groups; however, acute cellular rejection, ≥grade 2 (1990 ISHLT criteria), was more frequent among those having recently vaccinated (control: 1/45 vs. 6/15, p = 0.001). On multivariate analysis, the only risk factor found to be associated with acute cellular rejection was recent H1N1 viral antigen and adjuvant vaccination (OR 26.5: 95% CI 02.59-270.5). Vaccine adjuvants increase host response to vaccine antigens by immune upregulation potentially increasing risk of rejection in solid-organ transplant recipients. The potential hazard of vaccination this study raises must be weighed with the clear benefit vaccination has proven to be.
? 2011 The Authors Journal compilation ? 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.
PMID:
21906258
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21906258
Impact of Adjuvanted H1N1 Vaccine on Cell-Mediated Rejection in Heart Transplant Recipients.
Schaffer AS, Husain S, Delgado DH, Kavanaugh L, Ross RJ.
Source
Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada Division of Transplantation, Toronto General Hospital, University Health Network, Toronto, ON, Canada Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada.
Abstract
During the H1N1 influenza virus pandemic, vaccination of high risk groups including solid-organ transplant recipients was advised. A retrospective case control study of 60 heart transplant patients, 15 having received the H1N1 virus antigen and ASO3 adjuvant vaccine (GlaxoSmithKline, Mississauga, ON, Canada) within 21 days and 45 having not been vaccinated, all undergoing routine surveillance endmyocardial biopsies, was performed. The overall rate of cellular rejection (all grades) was not statistically different between groups; however, acute cellular rejection, ≥grade 2 (1990 ISHLT criteria), was more frequent among those having recently vaccinated (control: 1/45 vs. 6/15, p = 0.001). On multivariate analysis, the only risk factor found to be associated with acute cellular rejection was recent H1N1 viral antigen and adjuvant vaccination (OR 26.5: 95% CI 02.59-270.5). Vaccine adjuvants increase host response to vaccine antigens by immune upregulation potentially increasing risk of rejection in solid-organ transplant recipients. The potential hazard of vaccination this study raises must be weighed with the clear benefit vaccination has proven to be.
? 2011 The Authors Journal compilation ? 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.
PMID:
21906258
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21906258